Medtronic plc.NYSE: MDT

Endurant™ stent graft system first and only to receive CE-mark for updated rupture labeling

· Issued by Medtronic plc.

Summary by 6ix AI

Medtronic plc, a healthcare technology company, received Conformité Européenne (CE) approval, the European Union's product conformity marking, for its Endurant stent graft system. The approval removes the label warning on treating rAAA (ruptured abdominal aortic aneurysm, a burst bulge in the main artery in the abdomen).

Key details

  • Medtronic says Endurant is the first and only stent graft system to receive a CE mark for the updated rupture labeling.
  • The CE labeling update follows the U.S. Food and Drug Administration (FDA) labeling approval for Endurant received in October 2025.
  • Medtronic says the updated labeling in Europe supports expanded training and educational opportunities there.

6ix AI wrote this summary from the release below and checked it against the release.

Medtronic plc, a global leader in healthcare technology, today announced it has received Conformité Européenne (CE) approval1 for the Medtronic Endurant™ stent graft system to remove the rAAA treatment warning. The CE Mark labeling update follows the U.S. FDA labeling approval received in October 2025 and extends updated Endurant rAAA labeling to support expanded training and educational opportunities in Europe. [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Medtronic plc. on 6ix

Story so far

Earlier from Medtronic

Later from Medtronic

All Medtronic news releases